U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07481058) titled 'A Study of KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy as First-line Treatment in Patients With Advanced Esophageal Cancer' on March 14.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of KC1036 in combination with PD-1 antibody and platinum-based chemotherapy as a first-line treatment for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).
Study Start Date: Dec. 12, 2025
Study Type: INTERVENTIONAL
Condition:
Esophageal Squamous Cell Carcinoma (ESCC)
Intervention:
DRUG: KC1036
Dosage: 20 mg, 30 mg, or 40 ...